ArticleFrontiers in nutrition2025
Eight weeks of creatine monohydrate supplementation is associated with increased muscle strength and size in Alzheimer's disease: data from a single-arm pilot study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Creatine to Augment Bioenergetics in Alzheimer's
Examining the Effects of Creatine Supplementation and Resistance Training on Cognition and Brain Health in Older Adults With Mild Cognitive Impairment: a 26 Week Randomized Controlled Trial
Who cites it
2 citing papers in PubMed.
- A peripheral perspective on brain health: vascular and skeletal muscle contributions.American journal of physiology. Heart and circulatory physiology · 2026Review
- Liposomal and Polymeric Drug Delivery of Creatine: Exploring a Multifaceted Molecule for Neurodegenerative Diseases and Beyond.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: To investigate the potential muscular benefits of an eight-week creatine monohydrate (CrM) supplementation in patients with Alzheimer's disease (AD). Methods: This single-arm pilot trial, conducted at the University of Kansas Medical Center in Kansas City, examined the intervention-associated changes in muscle strength, muscle size, and neuromuscular junction (NMJ) integrity following 8 weeks of CrM supplementation (20 g/day) in 20 participants with AD. All participants completed handgrip-strength measurements on the dominant hand (highest of three trials in kg of force). Ten participants completed lower body strength assessment via leg dynamometry at three velocities (1.05 rad∙s Results: Following 8 weeks of CrM, mean hand-grip strength increased by 1.9 kg from baseline ( Conclusion: This eight-week pilot trial suggests that 20 g/day of CrM may provide modest skeletal muscle benefits in patients with AD. These data provide preliminary evidence to warrant further investigation of the potential for CrM to prevent AD-related decline in muscle function. Clinical trial registration: ClinicalTrials.gov, identifier NCT05383833.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.